NEW YORK, Aug. 17, 2023 /PRNewswire/ -- Dolby Laboratories Inc. (NYSE:DLB) will replace Staar Surgical Co. (NASD:STAA) in the S&P MidCap 400 and Staar Surgical will replace Urstadt Biddle Properties Inc. (NYSE:UBA) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, August 22. S&P 500 constituent Regency Centers Corp. (NASD: REG) will acquire Urstadt Biddle Properties in a transaction expected to close soon pending final closing conditions. Staar Surgical is more representative of the small-cap market space.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date | Index Name | Action | Company Name | Ticker | GICS Sector |
August 22, 2023 | S&P MidCap 400 | Addition | Dolby Laboratories | DLB | Information Technology |
S&P MidCap 400 | Deletion | Staar Surgical | STAA | Health Care | |
S&P SmallCap 600 | Addition | Staar Surgical | STAA | Health Care | |
S&P SmallCap 600 | Deletion | Urstadt Biddle Properties | UBA | Real Estate |
For more information about S&P Dow Jones Indices, please visit www.spdji.com
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.
FOR MORE INFORMATION:
S&P Dow Jones Indices
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$17.24 |
Daily Change: | -0.77 -4.28 |
Daily Volume: | 163,925 |
Market Cap: | US$849.340M |
February 26, 2025 February 11, 2025 October 30, 2024 August 07, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load